Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases

This publication has 9 references indexed in Scilit:

• Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations
  Allergy, 2022
• Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
  New England Journal of Medicine, 2021
• Combination Anti-IgE and Anti-IL5 Therapy in a Pediatric Patient With Severe Persistent Asthma
  The Journal of Pediatric Pharmacology and Therapeutics, 2021
• Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
  Frontiers in Pharmacology, 2020
• Combination biologic therapy for severe persistent asthma
  Annals of Allergy, Asthma & Immunology, 2019
• Combining Omalizumab with Another Biotherapy
  Acta Dermato-Venereologica, 2019
• Cost-effectiveness and comparative effectiveness of biologic therapy for asthma
  Annals of Allergy, Asthma & Immunology, 2019
• COMBINATION BIOLOGIC THERAPY IN SEVERE ASTHMA: A CASE SERIES
  Annals of Allergy, Asthma & Immunology, 2018
• Combination anti-IgE and anti-IL5 therapies in patients with severe persistent asthma and allergic bronchopulmonary aspergillosis (ABPA)
  Journal of Allergy and Clinical Immunology, 2018